State of New Jersey Common Pension Fund D Decreases Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

State of New Jersey Common Pension Fund D decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) by 6.5% during the first quarter, HoldingsChannel reports. The institutional investor owned 78,484 shares of the specialty pharmaceutical company’s stock after selling 5,431 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Supernus Pharmaceuticals were worth $2,537,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. FDx Advisors Inc. lifted its position in shares of Supernus Pharmaceuticals by 10.4% during the 1st quarter. FDx Advisors Inc. now owns 7,766 shares of the specialty pharmaceutical company’s stock valued at $251,000 after buying an additional 733 shares in the last quarter. C M Bidwell & Associates Ltd. lifted its position in shares of Supernus Pharmaceuticals by 97.8% during the 1st quarter. C M Bidwell & Associates Ltd. now owns 2,922 shares of the specialty pharmaceutical company’s stock valued at $94,000 after buying an additional 1,445 shares in the last quarter. Euclidean Technologies Management LLC purchased a new position in shares of Supernus Pharmaceuticals during the 1st quarter valued at approximately $208,000. DekaBank Deutsche Girozentrale lifted its position in shares of Supernus Pharmaceuticals by 9.9% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 22,200 shares of the specialty pharmaceutical company’s stock valued at $719,000 after buying an additional 2,000 shares in the last quarter. Finally, Campbell Newman Asset Management Inc. lifted its position in shares of Supernus Pharmaceuticals by 2.0% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 22,696 shares of the specialty pharmaceutical company’s stock valued at $734,000 after buying an additional 443 shares in the last quarter.

Supernus Pharmaceuticals Stock Down 0.8 %

NASDAQ SUPN opened at $31.50 on Tuesday. The business has a fifty day moving average price of $28.72 and a 200 day moving average price of $29.73. Supernus Pharmaceuticals, Inc. has a one year low of $23.15 and a one year high of $34.50. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.69 and a current ratio of 2.00. The company has a market cap of $1.68 billion, a P/E ratio of 24.42 and a beta of 1.04.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last posted its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.26 by $0.17. The firm had revenue of $152.50 million during the quarter, compared to the consensus estimate of $150.47 million. Supernus Pharmaceuticals had a return on equity of 9.05% and a net margin of 12.20%. The firm’s revenue was up 16.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.11 EPS. Research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. StockNews.com upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 18th. TheStreet downgraded Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, April 18th.

Supernus Pharmaceuticals Profile

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Featured Articles

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.